MorphoSys Lifts FY13 Outlook - Quick Facts

(RTTNews) - MorphoSys AG (MPSYY.PK) Thursday said it currently expects to report full-year 2013 revenues in the upper-end of its previous guidance range of 74 million euros to 78 million euros.

Full-year EBIT is projected in the range of 7 million euros to 10 million euros, up from its previous guidance range of 2 million euros to 6 million euros.

The change of the EBIT range is mainly driven by the positive revenue development and lower than originally anticipated costs for the development of the cancer program MOR202 under the co-development and cost-sharing agreement with Celgene.